Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is listed today as Neumora Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
0 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2020 | $474 M | Issued in a merger or acquisition | $250 million to $1 billion | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Neumora Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2023).
SEC Form D · Jan 2023
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jan 2023
That is all the official record says: Neumora Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Neumora Therapeutics, Inc. are on record.
Investors#
16 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Amgen Inc | Company | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| ARCH Venture Fund VIII Overage, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| Arch Venture Fund VII LP | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| ARCH Venture Fund XII, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| ARCH Venture Fund X, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| ARCH Venture Fund X Overage, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| ARCH Venture Partners VIII, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| ARCH Venture Partners VII, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| ARCH Venture Partners VII, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| ARCH Venture Partners XII, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| ARCH Venture Partners XII, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| ARCH Venture Partners X, LLC | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| ARCH Venture Partners X, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| ARCH Venture Partners X Overage, L.P. | Venture capital | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| Fmr LLC | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| Kristina Burow | Person | not stated | not stated | Held Series A-1 preferred stock, 10% owner, director (Form 3, 2023) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.
Largest shareholders today
Institutions holding Neumora Therapeutics, Inc. shares, as of Sep 30, 2026.
- ARCH Venture Management, LLC$20 M18.01%
- Siren, L.L.C.$5 M4.52%
- BlackRock, Inc.$5 M4.33%
- Softbank Group Corp.$4 M3.24%
- Vanguard Capital Management LLC$3 M2.49%
- Affinity Asset Advisors, LLC$3 M2.39%
- MIC Capital Management UK LLP$3 M2.37%
- Exor N.V.$3 M2.24%
- WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST$2 M1.76%
- AQR Capital Management LLC$2 M1.63%
- Geode Capital Management, LLC$2 M1.49%
- FMR LLC$2 M1.39%
- ICONIQ Capital, LLC$2 M1.36%
- Lunate Capital Ltd$1 M1.13%
- Johnson & Johnson$1 M0.98%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Joshua Pinto | Executive officer | Jan 2023 |
| Paul Berns | Executive officer | Jan 2023 |
| Tamara Tompkins | Executive officer | Jan 2023 |
| Alaa Halawa | Director | Jan 2023 |
| Kari Stefansson | Director | Jan 2023 |
| Kristina Burow | Director | Jan 2023 |
| Matthew Fust | Director | Jan 2023 |
| Maykin Ho | Director | Jan 2023 |
| Paul Berns | Director | Jan 2023 |
| Robert Nelsen | Director | Jan 2023 |
| Stacie Weninger | Director | Jan 2023 |
Went public since 2023. Its SEC number is that of a company listed on a stock exchange.